New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
12:43 EDTTUR, TWX, CRIS, NTEHigh option volume stocks: XBI TWX NTE CRIS TUR
News For TWX;NTE;CRIS;TUR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 25, 2015
13:26 EDTTWXWarner Bros.' 'American Sniper' keeps top spot at box office, WSJ says
Subscribe for More Information
January 22, 2015
15:29 EDTTWXTime Warner names Mitchell Klaif as Chief Information Officer
Subscribe for More Information
08:20 EDTCRISCuris price target raised to $5 from $3 at Oppenheimer
Subscribe for More Information
January 21, 2015
07:34 EDTTWXNetflix CEO sees room for competition in video streaming market, CNet says
Subscribe for More Information
07:34 EDTCRISCuris to host conference call
Conference call to discuss the Curis-Aurigene transaction will be held on January 21 at 8 am. Webcast Link
06:17 EDTTWXOverstock to introduce streaming-video service later this year, WSJ reports
Overstock.com (OSTK) is planning to launch a streaming-video service later this year, CEO Patrick Byrne announced at the National Association of Television Program Executives conference, The Wall Street Journal reports. Overstock would compete in the space with Amazon (AMZN), Hulu (DIS, CMCSA, CMCSK, FOXA), Netflix (NFLX), and Time Warner's (TWX) HBO is also planning a standalone online streaming service that will launch this year. The new Overstock service would be tied to the company's $20-per-year Club O membership program and will launch with about 30,000 titles. Reference Link
06:07 EDTCRISCuris and Aurigene Discovery announce exclusive collaboration agreement
Curis and Aurigene Discovery Technologies announced that they have entered into an exclusive collaboration agreement focused on immuno-oncology and selected precision oncology targets. The collaboration provides for inclusion of multiple programs, with Curis having the option to exclusively license compounds once a development candidate is nominated within each respective program. The partnership draws from each company's respective areas of expertise, with Aurigene having the responsibility for conducting all discovery and preclinical activities, including IND-enabling studies and providing Phase 1 clinical trial supply, and Curis having responsibility for all clinical development, regulatory and commercialization efforts worldwide, excluding India and Russia, for each program for which it exercises an option to obtain a license. The first two programs under the collaboration are an orally-available small molecule antagonist of programmed death ligand-1 in the immuno-oncology field and an orally-available small molecule inhibitor of Interleukin-1 receptor-associated kinase 4 in the precision oncology field. Curis expects to exercise its option to obtain exclusive licenses to both programs and file IND applications for a development candidate from each in 2015. The agreement provides that the parties will collaborate exclusively in immuno-oncology for an initial period of approximately two years, with the option for Curis to extend the broad immuno-oncology exclusivity.In addition Curis has agreed to make payments to Aurigene as follows: For the first two programs: up to $52.5 million per program, including $42.5 million per program for approval and commercial milestones, plus specified approval milestone payments for additional indications, if any; For the third and fourth programs: up to $50 million per program, including $42.5 million per program for approval and commercial milestones, plus specified approval milestone payments for additional indications, if any; and for any program thereafter: up to $140.5 million per program, including $87.5 million per program in approval and commercial milestones, plus specified approval milestone payments for additional indications, if any. Curis has agreed to pay Aurigene royalties on any net sales ranging from high single digits to 10% in territories where it successfully commercializes products and will also share in amounts that it receives from sublicensees depending upon the stage of development of the respective molecule.
January 20, 2015
17:46 EDTTWXNetflix says 'looking good' to reach 60M-90M U.S. subscriptions
Subscribe for More Information
14:06 EDTTWXCitizens, Keysight identified as long positions by Einhorn
Subscribe for More Information
13:24 EDTTWXGreenlight has new long positions in Citizens, Time Warner, Bloomberg says
Subscribe for More Information
07:35 EDTTWXTime Warner downgraded at Morgan Stanley
As previously reported, Morgan Stanley downgraded Time Warner to Equal Weight from Overweight. The firm downgraded shares based on balanced risk/reward, and downside risk from affiliate fee growth and TV advertising. Price target lowered to $85 from $90.
06:29 EDTTWXTime Warner downgraded to Equal Weight from Overweight at Morgan Stanley
January 18, 2015
16:46 EDTTWXWarner Bros.' 'American Sniper' takes top spot with $90.2M at box office
Subscribe for More Information
January 16, 2015
10:01 EDTTWXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
January 15, 2015
16:23 EDTTWXTime Warner downgraded to Hold from Buy at Stifel
Subscribe for More Information
January 13, 2015
06:28 EDTTWXCNN reaches deal with FAA to study use of drones in reporting, WSJ reports
Subscribe for More Information
January 12, 2015
09:15 EDTTWX'Taken' seqeul knocks 'Hobbit' from top spot at box office, WSJ reports
Subscribe for More Information
09:04 EDTTWXAmazon wins first Golden Globe for 'Transparent,' Business Insider reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use